XML 50 R39.htm IDEA: XBRL DOCUMENT v3.19.1
Collaborative Arrangements - Narrative (Details) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 12 Months Ended 21 Months Ended 35 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2019
Apr. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Mar. 31, 2018
Dec. 31, 2017
Jul. 31, 2017
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Dec. 31, 2017
Mar. 31, 2019
Jan. 31, 2021
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Research and development                   $ 1,931 $ 3,196        
Other liabilities, noncurrent         $ 11,585 $ 12,041       11,585   $ 12,041   $ 11,585  
Lynparza | Other Assets                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Finite-lived intangible assets         724         724       724  
Lenvima | Other Assets                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Finite-lived intangible assets         711         711       711  
Adempas | Other intangible assets                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Finite-lived intangible assets         977         977       977  
AstraZeneca                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Upfront and milestone payments                         $ 1,600    
Payments to acquire intangible assets           400   $ 250 $ 750            
Research and development                         $ 2,350    
AstraZeneca | Forecast                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Payments to acquire intangible assets     $ 100                        
AstraZeneca | Sales-Based Milestones                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Probable contingent payments collaborative arrangement                           700  
Contingent milestone payments collaborative arrangement                   3,400          
AstraZeneca | Sales-Based Milestones | Lynparza                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Milestone payments made to collaborative partner                           250  
AstraZeneca | Regulatory Milestones | Lynparza                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Milestone payments made to collaborative partner                       140      
Eisai                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Upfront and milestone payments             $ 750                
Payments to acquire intangible assets         325                    
Research and development                     1,400        
Eisai | Forecast                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Payments to acquire intangible assets $ 125 $ 200                         $ 650
Eisai | Lenvima                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Cumulative amortization expense                   35          
Eisai | Sales-Based Milestones                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Contingent milestone payments collaborative arrangement             3,970     3,420          
Eisai | Sales-Based Milestones | Lenvima                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Probable contingent payments collaborative arrangement                   282   268      
Liabilities         $ 282         282       $ 282  
Eisai | Regulatory Milestones                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Contingent milestone payments collaborative arrangement             $ 385     135          
Eisai | Regulatory Milestones | Lenvima                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Milestone payments made to collaborative partner                       250      
Bayer AG | Sales-Based Milestones                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Probable contingent payments collaborative arrangement                       375      
Milestone payments made to collaborative partner                     $ 350        
Contingent milestone payments collaborative arrangement                   $ 400          
Other liabilities, noncurrent           $ 375           $ 375      
Subsequent Event | AstraZeneca | Regulatory Milestones | Lynparza                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Milestone payments made to collaborative partner       $ 30                      
Contingent milestone payments collaborative arrangement       $ 1,730